View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, May 3 (HealthDay News) -- For patients with thyroid cancer who undergo complete surgical resection, low-dose radioiodine plus thyrotropin is as effective as high-dose radioiodine, according to two studies published in the May 3 issue of the New England Journal of Medicine.
Martin Schlumberger, M.D., from the Institut Gustave Roussy and University Paris-Sud, and colleagues compared two thyrotropin stimulation methods, thyroid hormone withdrawal and use of recombinant human thyrotropin, and two radioiodine doses (1.1 GBq and 3.7 GBq) for treatment of low-risk thyroid cancer in 684 patients who had undergone complete surgical resection. The researchers found that ultrasonography of the neck was normal in 95 percent of patients. Thyroid ablation was complete in 92 percent of patients, and the ablation rate was comparable between the radioiodine doses and thyrotropin-stimulation methods.
Ujjal Mallick, M.D., from Freeman Hospital in Newcastle upon Tyne, U.K., and colleagues compared low- and high-dose radioiodine (1.1 and 3.7 GBq, respectively) in combination with thyrotropin alfa or thyroid hormone withdrawal before ablation in 438 patients with T1 to T3 thyroid tumors with possible spread to nearby lymph nodes but no metastasis. Upon analyzing the data for 421 patients, the researchers found that low-dose radioiodine was as effective as high-dose radioiodine (ablation success rates of 85.0 versus 88.9 percent, respectively). Similar results were seen for low-dose radioiodine plus thyrotropin alfa and for high-dose radioiodine with either thyroid hormone withdrawal or thyrotropin alfa (84.3 versus 87.6 and 90.2 percent, respectively).
"Low-dose radioiodine plus thyrotropin alfa is an effective and convenient treatment with reduced radiation exposure," Mallick and colleagues write.
Two of the authors from the Schlumberger study disclosed financial ties to Genzyme.
Full Text - Schlumberger (subscription or payment may be required)
Full Text - Mallick (subscription or payment may be required)
Editorial (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top